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Abstract
Background: A given tumor is usually dependent on the oncogene that is activated in the respective tumor entity. This
phenomenon called oncogene addiction provides the rationale for attempts to target oncogene products in a therapeutic
manner, be it by small molecules, by small interfering RNAs (siRNA) or by antigen-specific T cells. As the proto-oncogene
product is required also for the function of normal cells, this raises the question whether there is a therapeutic window
between the adverse effects of specific inhibitors or T cells to normal tissue that may limit their application, and their
beneficial tumor-specific therapeutic action. To address this crucial question, suitable mouse strains need to be developed,
that enable expression of the human proto-oncogene not only in tumor but also in normal cells. The aim of this work is to
provide such a mouse strain for the human proto-oncogene product c-MYC.
Principal Findings: We generated C57BL/6-derived embryonic stem cells that are transgenic for a humanized c-Myc gene
and established a mouse strain (hc-Myc) that expresses human c-MYC instead of the murine ortholog. These transgenic
animals harbor the humanized c-Myc gene integrated into the endogenous murine c-Myc locus. Despite the lack of the
endogenous murine c-Myc gene, homozygous mice show a normal phenotype indicating that human c-MYC can replace its
murine ortholog.
Conclusions: The newly established hc-Myc mouse strain provides a model system to study in detail the adverse effects of
therapies that target the human c-MYC protein. To mimic the clinical situation, hc-Myc mice may be cross-bred to mice that
develop tumors due to overexpression of human c-MYC. With these double transgenic mice it will be possible to study
simultaneously the therapeutic efficiency and adverse side effects of MYC-specific therapies in the same mouse.
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Introduction
MYC-proteins (c-MYC, MYCN and L-MYC) represent a family
of transcription factors which are of particular therapeutic interest
because of their strong over-expression in many human cancers
[1]. The c-MYC gene codes for two proteins c-MYC1 (p67) and c-
MYC2 (p64), that arise from alternative start codons [2]. c-MYC1
is expressed from a CUG start codon in exon 1 and c-MYC2 from
the AUG codon in exon 2. In normal cells c-MYC2 is expressed in
nearly all proliferating cells, whereas c-MYC1 is expressed when
the cells are starved of methionine at high cell density [2–4]. Both
c-MYC isoforms act as transcriptional activators and also as
repressors of several genes. Among the c-MYC target genes are
genes which regulate the synthesis of nucleotides, the cell cycle, cell
proliferation, cell growth, apoptosis and ribosome biogenesis [5,6].
c-MYC heterodimerizes with a partner protein called MAX to
exert transcriptional regulation [6]. MYC-MAX dimers are able to
bind to specific DNA-sequences, called E-boxes, for transcriptional
regulation of genes. Negative regulators of MYC are MIZ-1 [7]
and proteins of the MXD family, e.g. MAD1, MAD3, MAD4 and
MXI-1 [6–8], which can also interact with MAX instead of MYC
and block binding to E-boxes.
In several neoplasms c-MYC2 is overexpressed due to
chromosomal translocation, gene amplification or abnormal
transcriptional or translational regulation [1,9–12]. Interestingly,
by using conditional c-MYC-expressing mouse strains [13–16] or
by inhibiting the function of c-MYC in vivo [17] it could be shown
that c-MYC overexpression is also important for the maintenance
of the cancerous stage of MYC-driven tumors. This MYC-
dependency emphasizes the potential of MYC-specific cancer
therapies.
Several strategies using different kinds of antisense oligonucleo-
tides or peptide nucleic acids have been tested in cell systems and
also in mouse strains for their effectiveness in inhibiting the MYC-
induced proliferation of cancer cell lines [18–22]. In other studies
small molecules were analyzed that interfere with the interaction
of MYC and MAX or block the action of MYC in a different
fashion [22,23].
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In our group we are interested in generating c-MYC-specific T
cells for specific elimination of MYC-overexpressing tumor cells.
One major question regarding this strategy is, whether there is
a therapeutic window in which c-MYC specific T cells eliminate
all tumor cells but do not cause fatal damage to healthy tissue.
Likewise, for other MYC-targeting strategies it should also be of
major concern to analyze in detail the adverse effects on healthy
MYC-expressing tissue. However, pre-clinical in vivo model
systems are not available to address these issues.
To fill this gap, we report here the generation of a C57BL/6
(B6) mouse strain named hc-Myc, in which the endogenous c-Myc
gene is replaced by a humanized c-Myc (hc-Myc) gene. These
animals express human c-MYC instead of the endogenous murine
protein under physiological conditions. In this mouse strain
strategies for targeting the human c-MYC protein can be studied.
By cross-breeding humanized c-Myc mice to mouse strains that
develop tumors as a consequence of overexpression of human c-
MYC in pre B cells, prostate, astroglial, and B cells, like the
EnMYC [24], Hi-Myc [25], GFAP/c-Myc [26] or l-MYC mice
[27] and targeting the human c-MYC protein by small molecules,
siRNAs or T cells, it will become feasible to dissect therapeutic
effects from adverse side effects.
Materials and Methods
Generation of the Targeting Vector
The B6 murine c-Myc locus was derived from a bacterial
artificial chromosome. The murine c-Myc locus was retrieved as
a fragment of about 14 kb by homologous recombination into
plasmid pL255 (kindly provided by Ingo Burtscher), which
contains a HSV-TK gene. Fragments encompassing about
500 bp each upstream and downstream of the coding region
were amplified by PCR and inserted into a plasmid containing the
human c-MYC gene, originally derived from the normal allele of
a Burkitt lymphoma patient. A Neomycin-Geneticin resistance
gene, flanked by loxP-sites, was inserted into the BglII restriction
site in the second intron of human c-MYC. The human c-MYC
coding region, intron 1, intron 2 and the Neomycin-Geneticin
resistance cassette were inserted into the retrieval vector harboring
the murine c-Myc locus by homologous recombination in E. coli
using kanamycin selection. The coding sequence of the chimeric
murine-human construct was thus of human origin from the CUG
codon in exon 1 onwards, whereas non-coding regulatory regions
in exon 1 and exon 3 were kept murine. In exon 3 the human
sequence exceeds the stop codon by 69 bp. The introns 1 and 2
are of human origin. The HSV-TK gene which resided outwards
the arms for homologous recombination was used for selection of
Figure 1. Targeting strategy for homologous recombination in ES cells. The endogenous murine c-Myc gene was replaced with a humanized
c-Myc gene (hc-Myc). hc-Myc has human DNA sequences from the first translation start side (CUG) up to 69 bp downstream of the stop codon (TAA).
Non-coding sequences in exon 1 and exon 3 are of murine origin so that human c-MYC is expressed under the control of murine regulatory elements.
(A) Endogenous murine c-Myc with its three exons (E1, E2, E3) and the three promoters (P1, P2, P3). Indicated are the two start codons (CUG, AUG)
and the stop codon (TAA), as well as the flanking EcoRI restriction sites. (B) Murine c-Myc locus after homologous recombination with the targeting
vector. Indicated in black are human sequences, in grey murine sequences and with triangles the two loxP-sites that flank the Neomycin-Geneticin
resistance gene. (C) Recombined murine c-Myc locus after Cre-mediated deletion of the Neomycin-Geneticin resistance gene. A piece of mouse
chromosome 15 (position 61.985.920 to 61.989.995) is replaced by a piece of human chromosome 8 (position 128.748.840 to 128.753.273). Dotted
lines indicate recombination events. This schematic view displays EcoRI restriction sites, length of fragments after EcoRI-digestion, the sequence in the
junction region between human and murine elements and the regions where the Southern blot probes (59 probe and 39 probe) bind. Cre = Cre
recombinase.
doi:10.1371/journal.pone.0042021.g001
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embryonic stem (ES) cell clones in which homologous recombi-
nation had taken place.
Generation of Transgenic Mice
For generation of transgenic mice B6-derived embryonic stem
cells (Bruce4) were used [28]. hc-Myc transgenic ES cell clones were
generated by standard methods and injected into Balb/c-derived
blastocysts [29]. Chimeric mice were cross-bred to B6 mice. To
delete the Neomycin-Geneticin resistance gene, mice were cross-
bred to Cre-transgenic B6 deleter mice [30]. Breeding and
maintaining mice was carried out under specific pathogen-free
conditions (SPF).
Southern Blot
For Southern blot analysis genomic DNA of ES cells was
prepared by incubating ES cells o/n at 56uC in lysis buffer
(10 mM Tris pH 7,4, 10 mM EDTA, 10 mM NaCl, 0,5% (w/v)
SDS, 10 mg/mL Proteinase K). After cell lysis genomic DNA was
precipitated with ethanol and digested o/n with EcoRI. DNA-
fragments were separated by length on an agarose gel (0.8%
agarose) and blotted o/n onto a nylon membrane. DNA was cross-
linked to the membrane by baking at 80uC for 1 hour.
With radioactively labeled DNA probes that bind 59 and 39 site
of the murine c-Myc locus (Figure 1) DNA-fragments containing
the c-Myc locus were detected. Probes were radioactively labeled
with 50 mCi a32-dCTP (Hartmann Analytic) by using the
Random Prime Labeling Kit (GE Healthcare) according to
manufacturer’s instructions.
PCR-analysis
Mice were screened for the presence of the transgene by PCR
analysis using primers specific for human and murine sequences in
intron 2: humyc fwd, 59-CACCAGGCTTAGATGTGGC-39;
mumyc fwd, 59-GCAGCTATCCCTCACGGGA-39 and a primer
specific for a sequence in the non-translated region in exon 3: myc
rev, 59-GGCTGAAGCTTACAGTCCC-39. For sequence analy-
sis exon DNA was amplified by PCR with the following primers:
exon1 fwd, 59-GACTCGCCTCACTCAGCTC-39; exon1 rev, 59-
GGCATTCGACTCATCTCAGC-39; exon2 fwd, 59-
GTGCGTCTCCGAGATAGCA-39; exon2 rev, 59-
GGCCCGTTAAATAAGCTGCC-39; exon3 fwd, 59-CAC-
CAGGCTTAGATGTGGC-39 and exon3 rev, 59-GA-
TAACCCCTTCCCATATTTG-39.
Western Blot
Western blot analysis of cell extracts was performed as
previously described [31]. Human c-MYC was detected by using
the antibody Y69, purchased from Abcam, diluted in TBST-buffer
(Tris buffered saline: 0.1 M Tris/HCl pH 7.5, 0.1 M NaCl,
0.02% (v/v) tween). Equal loading was confirmed by an antibody
raised against glyceraldehyde-3-phosphat-dehydrogenase
(MAB374, Millipore).
B Cell Isolation and in vitro Proliferation Assay
For isolation of mature splenic B cells, a-CD43-magnetic beads
(Miltenyi Biotec) were used according to manufacturer’s instruc-
tions.
In order to analyze in vitro proliferation, B cells were labeled
with 5 mM carboxyfluorescein succinimidyl ester (CFSE, Molec-
Figure 2. Confirmation of homologous recombination and c-MYC2 expression in ES cell clones. (A) Genomic DNA of ES cell clones 1, 14,
18 and 19 and of wildtype ES cells (wt Bruce 4) was digested with EcoRI. Digested DNA was analyzed by Southern blotting with a 59 probe and a 39
probe. (wt) DNA fragment of the wildtype c-Myc locus; (rec.) DNA-fragment of recombined hc-Myc locus. (B) Protein extracts were prepared of ES cell
clones 1, 14, 18 and 19 as well as of wildtype ES cells (wt Bruce 4) and of a human lymphoblastoid cell line (LCL 1.11). Human c-MYC2 (hu. c-MYC, ca.
62 kDa) was detected with antibody clone Y69. In wildtype ES cells murine c-MYC2 (mu. c-MYC, ca. 64 kDa) was detected. For loading control an
antibody specific for glyceraldehyde-3-phosphat-dehydrogenase (GAPDH; ca. 36 kDa) was used. Western blot results were reproduced five times.
doi:10.1371/journal.pone.0042021.g002
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ular Probes) for 5 minutes at 37uC as previously described [31]. B
cells were cultivated for up to 3 days in RPMI-medium containing
10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/
mL penicillin and 100 mg/mL streptomycin, 1 6 non-essential
amino acids and 50 mM ß-mercaptoethanol supplemented with
the following stimuli: lipopolysaccharide (LPS; 10–25 mg/mL;
Escherichia coli 055:B5; Sigma-Aldrich), IL-4 (10 ng/mL; mouse
recombinant; Sigma-Aldrich) and a-CD40 antibody (clone
HM40-3 eBioscience, 2.5 mg/mL;). Cultivation was performed
in 96-well plates.
Flow Cytometry
For flow cytometry, single cell suspensions of various lymphoid
organs were prepared and analyzed with a FITC-labeled a-B220-
antibody (clone RA3-6B2, BD Biosciences) and a PE-labeled a-
CD3-antibody (clone 145-2C11, BD Biosciences) with the
FACSCaliburTM (BD Biosciences). Data were analyzed using
CELLQuestTM software (BD Bioscience). To exclude dead cells
TO-PRO-3 staining was performed.
Ethics Statement
All experiments were done complying with the German Animal
Welfare act and were approved by the institutional committee on
animal experimentation and the Government of Upper-Bavaria.
Statistical Analysis
For statistical analysis a two-tailed student t-test was applied.
Results
Targeting Strategy
In order to generate a mouse strain in which the human c-MYC
protein is expressed under physiological regulation, we integrated
a humanized c-Myc (hc-Myc) gene by homologous recombination
into the endogenous murine c-Myc locus in embryonic stem (ES)
cells. The hc-Myc gene is composed of human c-MYC-coding
sequences and human intron sequences, whereas the non-coding,
regulatory regions are of murine origin (see Figure 1). This is
expected to lead to normal regulation of the transgenic c-Myc gene by
mouse regulatory elements. The human sequence encompasses the
region from theCUG start codon in exon 1 up to 69 bp downstream
of the stop codon so that both isoforms of the human c-MYCprotein
can be expressed, c-MYC1 starting from the alternate start codon
Figure 3. Mice transgenic for hc-Myc. (A) Example of a chimeric animal (chimerism of 60 to 70%) that was generated by injection of ES cell clone
14 into Balb/c blastocysts (day 3.5). (B) Chimeric animals were cross-bred to wildtype B6 mice yielding black progeny. Brother and sister matings of
hc-Myc heterozygous mice (tested by PCR analysis) gave rise to hc-Myc homozygous offspring. The picture represents a PCR analysis of the genotypes
of the offspring. For analysis genomic DNA was isolated from tail tissue. As controls genomic DNA of ES cell clones 1 and 14 was used. mu.c-Myc: PCR
product of murine c-Myc. hc-Myc: PCR product of hc-Myc. (C) Detection of human c-MYC2 (hu. c-MYC, 62 kDa) in splenic cells of homozygous hc-Myc
mice by Western blotting. In splenic cells of wildtype mice murine c-MYC2 was detected (mu. c-MYC, ca. 64 kDa). For positive control protein extracts
from a human lymphoblastoid cell line (LCL 1.11) were used. Glyceraldehyde-3-phosphat-dehydrogenase (GAPDH, 36 kDa) was used as loading
control.
doi:10.1371/journal.pone.0042021.g003
Humanized c-Myc Mouse
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CUG in exon 1 and c-MYC2 starting from AUG in exon 2. The
transgene was flanked by arms for homologous recombination that
enabled specific integration into one allele of the endogenousmurine
c-Myc locus in ES cells.
A Neomycin-Geneticin resistance gene was cloned into the
second intron of the transgene for positive selection. The resistance
gene was flanked by loxP-sites and could be deleted by cross-
breeding the mice to deleter mice that express the Cre-recombinase
ubiquitously from early embryonic stages on.
Generation of Recombinant B6 ES Cells, Expressing
Human c-MYC
For generation of transgenic hc-Myc mice, ES cells were
transfected with the linearized hc-Myc transgene and ES cell clones
in which the hc-Myc gene was integrated into one c-Myc allele by
homologous recombination were selected by using Geneticin and
Ganciclovir. For verification of homologous recombination
a Southern blot analysis was performed. Figure 1 shows that the
endogenous murine c-Myc locus is flanked by two EcoRI-restriction
sites. Since the recombined c-Myc locus carries an additional
internal EcoRI-restriction site, it is possible to distinguish between
the endogenous and the recombined c-Myc-locus by EcoRI-
digestion of genomic DNA and Southern blotting, as indicated
in Figure 1. For the endogenous locus one large band (ca. 20 kb)
should be detected in the Southern blot, whereas the same
digestion of the recombined locus results in two smaller fragments,
a 59 fragment and a 39 fragment (each ca. 11 kb).
Figure 2A shows an example of a Southern blot analysis of four
selected ES cell clones. As a negative control wildtype ES cells
were used. All four clones showed a band for the wildtype c-Myc
allele and a second band for the 59- (59 probe) as well as the 39- (39
probe) fragment of the recombined locus. Overall 27 ES cell
clones could be identified, that had shown this pattern of bands in
the Southern blot and thus carried the hc-Myc transgene integrated
into one wildtype c-Myc allele.
Additionally we analyzed by Western blotting whether these
four ES cell clones expressed the human c-MYC protein. As
positive control the EBV-immortalized human lymphoblastoid cell
line LCL1.11 was used. As shown in Figure 2B, all four clones
expressed the human c-MYC protein (62 kDa), whereas in
wildtype ES cells only murine c-MYC of slightly higher molecular
weight (64 kDa) was detectable [32]. Furthermore, to verify the
human sequence of the transgene and to exclude point mutations,
the coding sequence of the hc-Myc gene was sequenced in ES cells.
Generation of the hc-Myc Mouse Strain
The ES cell clones 1, 14, 18 and 19 carrying the hc-Myc gene
integrated into one allele of the endogenous c-Myc locus were
used for injection into Balb/c blastocysts. From ES cell clones 1,
14 and 19 we could establish chimeric offspring, but only two
chimeras deriving from ES cell clone 14 gave rise to transgenic
offspring.
Figure 3A shows an example of one chimeric mouse derived
from clone 14. This chimeric mouse was cross-bred to B6
animals. Brother-sister matings of their offspring gave rise to the
mouse line with the homozygous hc-Myc locus. PCR analysis of
tail DNA of the offspring revealed that some mice carried the hc-
Myc transgene in a heterozygous and others in a homozygous
fashion (Figure 3B). As also proven by PCR-analysis, both copies
of the endogenous murine c-Myc gene were deleted in
homozygous animals. This indicates that substitution of the
murine c-Myc gene, whose deletion is embryonically lethal in
mice, with the humanized gene is compatible with life [33].
In hc-Myc mice expression of the human c-MYC protein was
additionally confirmed by Western blotting, as shown in Figure 3C.
The coding sequence of the hc-Myc gene in transgenic mice was
finally verified again by PCR amplification and sequencing of the
amplification products.
hc-Myc Mice Display a Normal Phenotype
Progeny were born in the expected mendelian ratio and were
apparently normal with respect to fertility, litter size, pre- and
postnatal development. In experiments with hypomorphic
murine c-Myc alleles it has been shown previously that di-
minished c-MYC expression in mice resulted in reduced body
weight, reduced weight of all organs and reduced proliferation of
lymphoid cells in vitro [34]. Thus, if the human c-MYC protein is
unable to fully replace its murine homologue, one should expect
a similar phenotype. Therefore, heterozygous and homozygous
hc-Myc mice were analyzed for these parameters.
As shown in Figure 4, the body weight and the weights of the
spleen, kidney and liver was comparable between heterozygous
and homozygous hc-Myc mice, as well as wildtype B6 animals.
Additionally, the number of total cells, B cells (B220+) and T cells
(CD3+) was determined in the spleen, inguinal lymph nodes and
Figure 4. hc-Myc mice have normal body and organ weights.
Body weight (A) and organ weight of spleen (B), both kidneys (C) and
liver (D) were analyzed of heterozygous (B6 hc-Myc+/2, n = 5) and
homozygous hc-Myc (B6 hc-Myc+/+, n = 8) mice as well as of wildtype B6
mice (B6 wt, n = 8) at the age of 10 - 11 weeks. Each symbol represents
one mouse. The mean weight is indicated in the graphs with a black
line and shown at the top of the symbols. Where ever small differences
were observed, they were not significant.
doi:10.1371/journal.pone.0042021.g004
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in the bone marrow (Figure 5). In these experiments again no
difference between the three groups of mice was detected.
Finally, the in vitro proliferation of splenic B cells was analyzed
after stimulation with LPS, or a-CD40 and IL-4 (Figure 6).
Apparently, B cells derived from homozygous hc-Myc mice
showed similar proliferation rates as B cells derived from B6
wildtype mice after stimulation with either LPS or a-CD40 and
IL-4. Taken together, our results show that the human c-MYC
protein substitutes for the functions of its murine ortholog. This
indicates that hc-myc mice are ideal candidates for studying the
adverse effects of therapies in which the human c-MYC-protein
is targeted.
Discussion
We describe the generation of a mouse strain that contains
a humanized c-Myc (hc-Myc) gene integrated into the murine c-
Myc locus and expresses the human c-MYC protein. Thus, in the
homozygous situation the endogenous murine c-Myc gene is
deleted. Homozygous hc-Myc mice have a normal phenotype
with respect to body weight, organ weights and cell numbers in
lymphoid organs, and fertility indicating that the human c-Myc
protein can functionally replace its murine ortholog.
The hc-Myc gene contains human coding sequences and
murine regulatory sequences upstream of the start codon in exon
1 and downstream of the stop codon in exon 3. To redirect
homologous recombination to the sequences upstream and
Figure 5. Normal cell numbers in lymphoid organs of hc-Myc mice as compared to wildtype mice. Cell numbers in the spleen (A), both
inguinal lymph nodes (B) and bone marrow of one tibia (C) was analyzed of 10 – 11 week old heterozygous (B6 hc-Myc+/2, n = 5), homozygous (B6 hc-
Myc+/+, n = 5) hc-Myc mice, and of wildtype B6 mice (B6 wt, n = 5). Depicted are total cell numbers of the lymphoid organs as well as B cell numbers
(B220+) and T cell numbers (CD3+). Total cell numbers were counted using a Neubauer chamber. The percentage of B and T cells was determined by
flow cytometric analysis. Mean values are indicated in the graph with black lines and shown at the top of the symbols. Where ever small differences
were observed, they were not significant.
doi:10.1371/journal.pone.0042021.g005
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downstream of the coding region and to prevent additional
recombination events within the introns, the humanized
transgene also harbors human intron sequences. As regulatory
sequences for the less frequently used promoter P3 may reside in
the introns of the Myc gene [35], promoter P3 may not be
regulated in hc-Myc mice in exactly the same fashion as in the
endogenous murine c-Myc locus. Yet, these small differences may
apparently not be important for two reasons. Firstly, the
differences in the regulation of the P3 promoter between the
humanized and endogenous c-Myc gene on Myc transcription and
translation, if they exist, are probably minimal because human
and murine intron sequences are relatively similar. Secondly and
most importantly, 95% of transcripts are normally generated
from promoter P1 and P2 which reside upstream of the coding
region in exon 1 [35]. Thus, it may be anticipated that in hc-
Myc mice P1 and P2 are under the control of the regulatory
elements of the endogenous murine locus.
The hc-Myc mouse strain was generated for the analysis of
therapeutic prospects of c-MYC targeting strategies. To this end,
it will be useful to cross-breed hc-Myc mice with animals already
available that develop tumors due to an overexpression of human
c-MYC in pre B, B cells, prostate cells and astroglial cells [24–
27]. In this situation the animals shall develop tumors that
overexpress human c-MYC and shall express human c-MYC
also in healthy cells with high proliferative and regenerative
capacity, like hematopoietic and intestinal epithelial cells. Thus it
will be possible to figure out in this pre-clinical model whether
a therapeutic window exists for various strategies targeting
human c-MYC in malignant cells. For strategies using DNA or
RNA oligonucleotides as well as for strategies using peptide
nucleic acids it will be important to verify their location of
binding. If they bind to coding sequences in the exon or to
intron sequences of the human c-MYC gene they should have
specificity for the hc-Myc transgene and should be applicable in
this mouse strain. Especially for the evaluation of strategies that
target the human c-MYC gene product by antigen-specific T cells,
the hc-Myc mouse will be useful and necessary. We could show
that it is possible to induce a T cell response against the human
c-MYC protein in wildtype B6 mice by vaccination with c-MYC
peptides covering non homologous regions between murine and
human c-MYC (Helm et al., unpublished). Furthermore one
immunogenic CD8+ T cell epitope of the human c-MYC protein
could be identified in C57BL/6 mice that can be used for
exploring the feasibility of c-MYC-specific T cell therapies in hc-
Myc mice.
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